rs113093597 - RNU6-755P - LMX1A
Magnitude 4.5 · 1 study on file
Reported associations
-
A Genome-Wide Association Study of Bisphosphonate-Associated Atypical Femoral Fracture. - Calcified tissue international (2020) · Kharazmi M, Michaëlsson K, Schilcher J, Eriksson N, Melhus H, Wadelius M, Hallberg P · PubMed 31006051
Atypical femoral fracture is a well-documented adverse reaction to bisphosphonates. It is strongly related to duration of bisphosphonate use, and the risk declines rapidly after drug withdrawal. The mechanism behind bisphosphonate-associated atypical femoral fracture is unclear, but a genetic predisposition has been suggested. With the aim to identify common genetic variants that could be used for preemptive genetic testing, we performed a genome-wide association study. Cases were recruited mainly through reports of adverse drug reactions sent to the Swedish Medical Products Agency on a nation-wide basis. We compared atypical femoral fracture cases (n = 51) with population-based controls (n = 4891), and to reduce the possibility of confounding by indication, we also compared with b
Auto-generated from study metadata. AI-synthesised commentary is added when this entry is regenerated through content-service's LLM mode.
Lifestyle context
Concrete actions anchored to the cited research. We do not prescribe, we describe.
Discuss with your doctor
-
bisphosphonate therapy if you are a variant carrier Moderate
Carriers of the A allele show 6-fold increased risk of atypical femoral fractures associated with bisphosphonate therapy in GWAS data.
Before starting or continuing bisphosphonates, inform prescriber of this genetic finding and discuss alternatives.